BioSpace News Archive

Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events in June.

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, presented data at the 2022 Epilepsy Foundation Pipeline Conference.

Orbis announces new research findings demonstrating that diabetic retinopathy screenings supported by artificial intelligence enhanced patients’ speed and uptake of referral services in Rwanda, which can help reduce vision loss due to diabetes in the region.

Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today is announcing data on AL101 from the Phase 2 ACCURACY study in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1) across three distinct platforms: Oral Delivery, Therapeutics, and Regenerative Medicine, will showcase its discovery of Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) during its oral presentation today at the American Transplant Congress being held in Boston.

Research scientists and statisticians from UC San Francisco have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janet Loesberg, Pharm. D., to its Board of Directors.

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Chief Executive Officer, Zachary Hornby, will present at the 2022 Jefferies Healthcare Conference, which will take place in New York City.

ASMS 2022 – Waters Corporation unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry 2022 Annual Conference.

Amarin Corporation plc announced the appointment of Tom Reilly as Chief Financial Officer, effective June 20, 2022.